Immunophenotypic Risk Factors for Low SARS-CoV-2 Immunization Response in Adults with Predominantly Antibody Deficiency over Five Total Vaccine Doses - 05/02/24
Doi : 10.1016/j.jaci.2023.11.784
Anna Zhang, MD 1, AHMED ELMOURSI, MD/MPH 2, Daniel Digiacomo, MD 2, Baijun Zhou 2, Megha Tandon, BA 2, Joseph Hong, BS 2, Nancy Yang, BS 2, Mei-Sing Ong, PhD 3, Anand Dighe, MD/PhD 2, Cristhian Berrios, MD 2, Mark Poznansky, MD/PhD 4, Anthony Iafrate, MD/PhD 2, Vivek Naranbhai, PhD/MB/ChB 5, Alejandro Balazs, PhD 6, Shiv Pillai, MBBS/PhD 6, Sara Barmettler, MD 2, Jocelyn Farmer, MD/PhD 7
1 Tufts Children's Hospital, Boston, Massachusetts
2 Massachusetts General Hospital, Boston MA
3 Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston MA
4 Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston MA
5 Dana-Farber Cancer Institute, Boston MA
6 Ragon Institute of Massachusetts General Hospital, Boston MA
7 Beth Israel Lahey Health, Harvard Medical School, Boston MA
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
756
Le texte complet de cet article est disponible en PDF.Plan
© 2023
Vol 153 - N° 2S
P. AB244 - février 2024 Retour au numéro
Article précédent
- IgE Sensitization Profiling Unveils Potential Risks of Fatal Asthma
- Amanda Atanasio, Abigail von Recklinghausen, YoonSeung Lee, Andre Limnander, Donna Farber, Matthew Sleeman, Jamie Orengo
- SARS-CoV-2 Vaccine Response Following Five Total Vaccine Doses in Adult Patients with Predominantly Antibody Deficiency (PAD)
- AHMED ELMOURSI, Anna Zhang, Daniel Digiacomo, Baijun Zhou, Megha Tandon, Joseph Hong, Nancy Yang, Mei-Sing Ong, Anand Dighe, Cristhian Berrios, Mark Poznansky, Anthony John Iafrate, Vivek Naranbhai, Alejandro Balazs, Shiv Pillai, Jocelyn Farmer, Sara Barmettler
Bienvenue sur EM-consulte, la référence des professionnels de santé.